is the first
and only FDA-approved
treatment for patients with
primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or
intolerance with conventional HLH therapy.
Gamifant starts here
We’re here to help
If you are considering treatment with Gamifant or need more information, call Gamifant Patient